Minimal Clinically Important Difference of Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI).
MCID
Vestibular Migraine Patient Assessment Tool and Handicap Inventory
minimal clinically important difference
vestibular migraine
Journal
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
ISSN: 1097-6817
Titre abrégé: Otolaryngol Head Neck Surg
Pays: England
ID NLM: 8508176
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
revised:
04
10
2024
received:
29
05
2024
accepted:
12
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
To calculate the minimal clinically important difference (MCID) for the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI). Prospective cohort study. A single tertiary care balance and falls center. Fifty-three subjects meeting Barany Society criteria for vestibular migraine (VM) or probable VM were included and divided into 3 treatment groups. Treatment was not standardized, instead, management was decided individually between each patient and their provider. All subjects completed VM-PATHI before and after intervention. A Global Rating of Change (GRoC) questionnaire was also completed following intervention. Anchor-based methods, using a GRoC questionnaire, were utilized to estimate the MCID that produced the highest sensitivity and specificity on a receiver operating characteristic (ROC) curve. Forty-three subjects were classified as responders and 10 were classified as nonresponders. The mean VM-PATHI pretreatment score minus the posttreatment score between the responders (mean = 14, SD 13) and nonresponders (mean = 4 SD = 12) was statistically significant (mean difference = 10, 95% confidence interval, CI [1, 20], P = .03). The VM-PATHI score change cutoff that best differentiated between responders and nonresponders was a VM-PATHI change of 6. Thus, the MCID was defined as a change of 6 points (sensitivity = 72%, specificity = 70%). The area under the ROC curve was 0.89, 95% CI [0.80, 0.98], which demonstrates an excellent ability for the VM-PATHI score change to discriminate between responders and nonresponders. The average change in VM-PATHI scores was 9 points (SD 11) for those with "a little better" rating on the GRoC, 14 points (SD 14) for those with a "moderately better" rating, and 20 points (SD 13) for those with a "very much better" rating. Patients with VM are likely to demonstrate clinical improvement if their VM-PATHI score decreases by 6 or more.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Academy of Otolaryngology–Head and Neck Surgery Foundation.
Références
Formeister EJ, Rizk HG, Kohn MA, Sharon JD. The epidemiology of vestibular migraine: a population‐based survey study. Otol Neurotol. 2018;39(8):1037‐1044.
Lempert T, Olesen J, Furman J, et al. Vestibular migraine: diagnostic criteria. J Vestib Res. 2012;22(4):167‐172.
Sharon JD, Krauter R, Kirk L, et al. Development and validation of VM‐PATHI: Vestibular Migraine Patient Assessment Tool and Handicap Inventory. Otol Neurotol. 2020;41(4):e494‐e500.
Kim EK, Hum M, Sharon JD. Correlating Vestibular Migraine Patient Assessment Tool and Handicap Inventory to daily dizziness symptoms. Otol Neurotol. 2023;44(10):1052‐1056.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Controlled Clin Trials. 1989;10(4):407‐415.
Sedaghat AR. Understanding the minimal clinically important difference (MCID) of patient‐reported outcome measures. Otolaryngol Head Neck Surg. 2019;161(4):551‐560.
Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health‐related quality of life. J Clin Epidemiol. 2003;56(5):395‐407.
Copay AG, Subach BR, Glassman SD, Polly Jr DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7(5):541‐546.
Engel L, Beaton DE, Touma Z. Minimal clinically important difference. Rheumatic Dis Clin North Am. 2018;44(2):177‐188.
Malec JF, Ketchum JM. A Standard Method for Determining the Minimal Clinically Important Difference for Rehabilitation Measures. Arch Phys Med Rehabil. 2020;101(6):1090‐1094.
Hosmer Jr DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. John Wiley & Sons; 2013.
Formeister EJ. Mindfulness‐based stress reduction for the treatment of vestibular migraine: a prospective trial. Presented at: Barany Society Meeting; May 9, 2022; Madrid, Spain.
Sharon JD. A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: the INVESTMENT study. Presented at: Headache Cooperative of the Pacific Winter Conference; January 26, 2024; Ojai Valley, CA.
Fong E, Li C, Aslakson R, Agrawal Y. Systematic review of patient‐reported outcome measures in clinical vestibular research. Arch Phys Med Rehabil. 2015;96(2):357‐365.
Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg. 1990;116(4):424‐427.
Rizk HG, Velozo C, Shah S, Hum M, Sharon JD, Mcrackan TR. Item level psychometrics of the Dizziness Handicap Inventory in vestibular migraine and Meniere's disease. Ear Hear. 2023;45:106‐114. doi:10.1097/AUD.0000000000001405
Marchetti GF, Lin CC, Alghadir A, Whitney SL. Responsiveness and minimal detectable change of the dynamic gait index and functional gait index in persons with balance and vestibular disorders. J Neurologic Phys Ther. 2014;38(2):119‐124.
Wellons RD, Duhe SE, MacDowell SG, Hodge A, Oxborough S, Levitzky EE. Estimating the minimal clinically important difference for balance and gait outcome measures in individuals with vestibular disorders. J Vestibular Res. 2022;32(3):223‐233.
Dannenbaum E, Chilingarian G, Fung J. Validity and Responsiveness of the Visual Vertigo Analogue Scale. J Neurologic Phys Ther. 2019;43(2):117‐121.
Reploeg MD, Goebel JA. Migraine‐associated dizziness: patient characteristics and management options. Otol Neurotol. 2002;23(3):364‐371.
Benjamin T, Gardi A, Sharon JD. Recent developments in vestibular migraine: a narrative review. Am J Audiol. 2023;32(3S):739‐745.
United States Food and Drug Administration. Guidance for Industry: Patient‐Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. US FDA.